896 / 1631
Lenalidomide
Chanan-Khan, A. A. et al. J Clin Oncol; 26:1544-1552 2008
•
Immunomodulatory properties
•
Modulation of both cellular and
cytokine tumour cell
microenvironment
•
Activates T cell and NK response
to tumour cell
•
Down regulates pro-survival
cytokines
•
Enhanced ADCC activity with
rituximab